Grants and Contributions

Deliver business management programming to women business owners

Deliver the Leadership Engagement Training Program

Deliver the Board Member Training Program

Contribution as part of the Participant Funding Program to Mitaanjigamiing First Nation to assist in preparing for and engaging in Indigenous consultation activities and public participation opportunities associated with the environmental assessment process for the Bending Lake Iron Project.

Crisis-affected people, including those in host communities, are in need of basic health assistance, food and nutrition assistance, protection services, shelter, and water and sanitation.

With GAC’s support, Action Against Hunger (ACF) is helping address the basic health, nutrition, water, sanitation and hygiene, and protection needs of crisis-affected people in the departments of Guajira, Cesar and Norte de Santander in Colombia.

FTIR and Raman are common spectroscopic tools used in materials synthesis and characterization. Deep neural networks will be used to develop an efficient and accurate methodology for simulating accurate spectroscopic signatures at significantly lowered computation cost than currently possible. This study will focus on 2D materials, beginning with graphene. AI will be used to:
1. Produce approximate (yet accurate) spectra from atomic structures using supervised learning on a large dataset of first principles-based calculations. The deep neural network will interpolate those spectra at a fraction of the original cost of generating them. The target is to develop an AI model which allows simulation of spectra from much larger (and therefore complex) structures than currently possible.
2. Searching the space of possible structures to find a simulated spectra which best matches experimental signal. Genetic algorithms will be explored, where the objective function will be to minimize the KL divergence between the spectra produced by the neural network and the experimental signal.

Key business goals:
* Accelerate growth through digital marketing strategies while developing our own direct to consumer program. Manifest consistency, brand  relevance and consumer eduction. 
 

KINeSYS is requesting funds from the CanExport program to complete export market development activities in Australia and Singapore.

Designing a drug for a specific disease type is highly challenging due to tremendous molecular search space and limited understanding about the disease of interest. Successful discovery of a medicine for a target (gene/protein/pathway) usually last for many years and costs a private pharmaceutical organization billions of dollars, which in turn determines the unaffordable price of medicines in the Canadian and global markets. The emerging of massive biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provide an unprecedented opportunity for automatic design of new drugs with much faster pace and much lower cost, igniting hopes to discovery drugs for diseases where no medicines have been found yet. In this project, the aim is to develop a data- and AI-driven drug design platform/pipeline for precise and effective treatment of cancers and complex diseases. It is possible to take the advantages of NRC’s unique multidisciplinary expertise in AI, data science, and human health therapeutics, as well as recipient’s knowledge and facilities, to tackle challenges in every step of drug design. Project technologies and outcomes will be disruptive and beneficial to all Canadians. This project will focus on search for small molecules carbonic anhydrase IX (CAIX) novel inhibitors. The recipient will provide expertise in CAIX binding and enzymatic assays, wet lab validation and experimental analysis of designed drug candidates for inhibiting CAIX activity and impact to tumor growth in vitro and in vivo.

Designing a drug for a specific disease type is highly challenging due to tremendous molecular search space and limited understanding about the disease of interest. Successful discovery of a medicine for a target (gene/protein/pathway) usually last for many years and costs a private pharmaceutical organization billions of dollars, which in turn determines the unaffordable price of medicines in the Canadian and global markets. The emerging of massive biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provide an unprecedented opportunity for automatic design of new drugs with much faster pace and much lower cost, igniting hopes to discovery drugs for diseases where no medicines have been found yet. In this project, the aim is to develop a data- and AI-driven drug design platform/pipeline for precise and effective treatment of cancers and complex diseases. It is possible to take the advantages of NRC’s unique multidisciplinary expertise in AI, data science, and human health therapeutics, as well as recipient’s knowledge and facilities, to tackle challenges in every step of drug design. Project technologies and outcomes will be disruptive and beneficial to all Canadians. This project will focus on search for small molecules carbonic anhydrase IX (CAIX) novel inhibitors. The recipient will provide expertise in CAIX binding and enzymatic assays, wet lab validation and experimental analysis of designed drug candidates for inhibiting CAIX activity and impact to tumor growth in vitro and in vivo.